Evidence Based Medicine on FHIR Implementation Guide
1.0.0-ballot2 - STU 1 ballot International flag

Evidence Based Medicine on FHIR Implementation Guide, published by HL7 International / Clinical Decision Support. This guide is not an authorized publication; it is the continuous build for version 1.0.0-ballot2 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/HL7/ebm/ and changes regularly. See the Directory of published versions

Example Evidence: Proportion of Patients With Hypertension Control at 6 and 12 weeks - 6 weeks for QUARTET LDQT in NCT03640312

version: 26; Last updated: 2025-08-18 13:22:42+0000

Profile: NonComparativeEvidence

ArtifactPublicationStatus: Active

url: https://fevir.net/resources/Evidence/367911

identifier: FEvIR Object Identifier/367911, FEvIR Linking Identifier/NCT03640312-secondaryOutcomeMeasure-3-6-weeks-OG000

name: NCT03640312_secondaryOutcomeMeasure_3_6_weeks_OG000

title: Proportion of Patients With Hypertension Control at 6 and 12 weeks - 6 weeks for QUARTET LDQT in NCT03640312

citeAs:

Proportion of Patients With Hypertension Control at 6 and 12 weeks - 6 weeks for QUARTET LDQT in NCT03640312 [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 367911. Revised 2025-08-18. Available at: https://fevir.net/resources/Evidence/367911. Computable resource at: https://fevir.net/resources/Evidence/367911#json.

status: Active

author: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter:

publisher: Computable Publishing LLC

contact: support@computablepublishing.com

copyright:

https://creativecommons.org/licenses/by-nc-sa/4.0/

description:

This Evidence Resource is referenced in an example for the EBMonFHIR Implementation Guide.

variableDefinition

description:

QUARTET LDQT

note: ,

Outcome Measure Population Description: Modified intent to treat whereby all those participants with data at any follow-up time point and baseline to contribute to analyses will be included in analyses according to arm to which they were randomized, regardless of adherence to the study protocol.

Outcome Measure Denominator Units: Participants

variableRole: Population

observed: Patients randomized to the intervention arm took a once daily ultra-low-dose quadruple combination therapy (QUARTET LDQT). The LDQT is an overencapsulated combination pill comprising four types of blood pressure lowering medications each at ¼ standard doses. QUARTET includes candesartan 2mg, amlodipine besylate 1.25mg, indapamide 0.625mg, and bisoprolol 2.5mg. The individual components are currently approved and marketed within the United States. QUARTET LDQT: Ultra-low-dose combination therapy comprising four different blood pressure lowering drugs at 1/4 dosages. Taken once daily for 12 weeks. (Identifier: ClinicalTrials.gov Outcome Measurement Group Id/OG000)

variableDefinition

variableRole: Outcome

observed: Proportion of Patients With Hypertension Control at 6 and 12 weeks - 6 weeks (NCT03640312)

statistic

statisticType: Number (see protocol for details)

quantity: 0.6875 proportion of participants

SampleSizes

-KnownDataCount
*32